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Abstract To assess the importance of various regions of the 
androgen receptor (AR) in transcriptional regulation, we have 
compared its activation functions (AFs) in yeast and mammalian 
cells. The receptor's amino-terminal region contains a major 
transcriptional activator (AF-1) in both cell types, whereas AF-2 
in the ligand-binding domain (LBD) is very weak in mammalian 
cells but clearly functional in the yeast. Hormone-binding ability 
of LBD is mandatory for AF-2 to operate, as illustrated by 
mutated LBD constructs. The activity of AF-2 in yeast is 
severely attenuated when the hinge region is attached to LBD, 
suggesting that the former region modulates AF-2 in vivo, 
probably by presenting an interface for interacting proteins. 
© 1997 Federation of European Biochemical Societies. 
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1. Introduction 
Androgen receptor (AR) is a ligand-inducible transcription 
factor that mediates the effects of male sex steroids to the 
transcription machinery [1]. A R is a member of the nuclear 
receptor superfamily that comprises receptors for steroids, 
thyroid hormones, and retinoids [2,3]. AR, like other nuclear 
receptors, is a modular protein that encompasses three sepa-
rate and interchangeable domains with specific functions in 
transactivation, D N A recognition and hormone binding 
[2,3]. Previous studies from this and other laboratories have 
shown that the amino-terminal half of A R contains sequences 
mandatory for both activation and repression of transcription 
[1,4,5]. Very little is known about functional interactions be-
tween activation regions of transcription factors in general, 
and there is no clear sequence similarity in the amino-terminal 
transactivation domains (AF-ls) amongst the members of the 
nuclear receptor family [2,3]. Besides A F - 1 , another weaker 
transcription activation function (AF-2) has been identified in 
the ligand-binding domain (LBD) of other steroid receptors 
[3], but the presence of a comparable function in A R has not 
been demonstrated. Moreover, the functional role of the hinge 
region residing between the DNA-binding domain (DBD) and 
LBD has remained elusive. 
The basic mechanisms controlling R N A polymerase II-cat-
alyzed transcription are conserved throughout the eukaryotic 
kingdom, and many mammalian transcriptional activators 
also function in yeast and vice versa. For example, various 
"Corresponding author. Institute of Biomedicine, Department of 
Physiology, University of Helsinki, P.O. Box 9, FIN-00014 Helsinki, 
Finland. Fax: (358) (9) 191 8681. 
E-mail: olli.janne@helsinki.fi 
nuclear receptors behave as ligand-inducible transcriptional 
activators of reporter genes when expressed in the yeast Sac-
charomyces cerevisiae [6-11]. To gain better understanding of 
A R function, we have compared its transcription activation 
functions in yeast and mammalian cells. Our results indicate 
that the amino-terminal AF-1 is the major activating region of 
this receptor in both cell types, whereas AF-2 located in L B D 
functions poorly in mammalian cells, but is quite active in the 
yeast. The activity of AF-2 is severely at tenuated by the pres-
ence of the hinge region, suggesting that this latter region 
modulates - probably via protein-protein interactions - the 
activity of LBD. 
2. Materials and methods 
2.1. Materials 
[3H]Mibolerone and [3H]acetyl-CoA were from New England Nu-
clear Corp. (Boston, MA). Casodex and hydroxyflutamide were gifts 
from Zeneca Pharmaceuticals (Macclesfield, UK). Restriction endo-
nucleases and other DNA-modifying enzymes were purchased from 
Pharmacia Biotech (Uppsala, Sweden). pLex-a vector encoding bacte-
rial LexA and yeast strain L40 [MATa trpl-901 his3D200 leu2-3,112 
ade2 LYS2'.: (lexAop)i-HIS3 URA3-: (lexAop)g-lacZ] were gifts from 
Dr. S. Hollenberg [12] (Vollum Institute, Oregon Health Sciences 
University, Portland, OR). Yeast construct pGBT9 expressing Saccha-
romyces cerevisiae GAL4 DBD fusion proteins and the corresponding 
mammalian construct pM, pVP16 expressing fusion proteins with the 
transcriptional activation domain of herpes simplex virus (VP16), 
pG5CAT containing five GAL4-binding sites in front of the adenovi-
rus Elb TATA box sequence driving the chloramphenicol acetyltrans-
ferase (CAT) gene, and the yeast strain SFY526 were purchased from 
Clontech (Palo Alto, CA). 
2.2. Construction of expression plasmids 
LexA expression vectors encoding LexA fused to parts of LBD 
of human (h) AR [pLexA-LBD(657-919), pLexA-LBD(668-919), 
pLexA-LBD(657-909), amino acid residues in parentheses], to a hinge 
region-containing LBD [pLexA-HLBD(624-919)] and to a rat (r) AR 
lacking only the two amino-terminal residues [pLexA-rAR] were con-
structed by polymerase chain (PCR) reaction using Vent polymerase 
(New England Biolabs, Beverly, MA) and cloned in-frame to the 
carboxyl-terminus of LexA (Fig. 1A). Gal4 expression vectors encod-
ing GAL4 DBD fused to two amino-terminal (NT) transactivation 
regions of hAR [pGAL4-NT(141^t07) and pGAL4-NT(141-340)] 
and to LBD of hAR [pGAL4-LBD(657-919)j were also made by 
PCR and cloned in-frame to pGBT9 expression vector (Fig. IB). 
Mammalian expression vector pM-LBD(657-919) was constructed 
by inserting the indicated residues of hAR in-frame to GAL4 DBD. 
Correct nucleotide sequences of all constructs were verified by DNA 
sequencing using the Pharmacia ALF Express system (Pharmacia, 
Uppsala, Sweden). 
2.3. Reporter gene activity assays 
Yeast strains L40 and SFY526 were transformed with LexA and 
GAL4 fusion protein expression vectors, respectively, to generate a 
series of strains expressing the AR constructs. These strains were used 
to inoculate liquid media without ura and trp (only trp for GAL4 
constructs) in the presence or absence of 50 nM testosterone ± 5 uM 
antiandrogen, and the cultures were grown overnight at 30°C. One-ml 
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aliquots of the cultures were used to inoculate 8 ml of YPD media, 
and the cells were grown at 30°C with shaking until ODMo ■ reached 
a value of 0.5-1.0. p-Galactosidase activity in yeast cells was meas-
ured according to the instructions of the Clontech Matchmaker Two-
Hybrid System. Chinese hamster ovary (CHO) or green monkey kid-
ney (CV-1) cells (both from ATCC) were maintained in Dulbecco's 
minimal essential medium containing penicillin (25 U/ml), streptomy-
cin (25 U/ml), 10% (v/v) fetal bovine serum (FBS) and, for CHO cells, 
also non-essential amino acids. Cells were transfected using the cal-
cium phosphate precipitation method as described previously [4,5]. 
|3-Galactosidase expression plasmid pSVP-gal served as an internal 
control for transfection efficiency. Eighteen hours after transfection, 
the medium was changed to one containing charcoal-stripped 2% (v/v) 
FBS in the presence or absence of androgen. CAT and P-galactosidase 
activities were assayed as previously described [4,5]. 
2.4. Ligand-binding assays in yeast cells 
Selective media were inoculated with a single colony of yeast, and 
the cultures were incubated by shaking overnight at 30°C. Yeast cells 
were then diluted to OD60o nm of 0.2 using YPD medium, and 
[3H]mibolerone was added to a final concentration of 50 nM in the 
presence or absence of a 100-fold molar excess of non-radioactive 
testosterone. After 2 h at 30°C, cells were harvested by centrifugation, 
washed twice with cold phosphate-buffered saline and once with dis-
tilled water. Cell pellets were resuspended in 0.2 ml of lysis buffer 
[20 mM Tris-HCl (pH 7.5), 1% NaDodS04] containing 80 mg of glass 
beads (Sigma, St. Louis, MO) and vortexed vigorously for 2 min. 
After centrifugation at 16000Xg for 10 min, the radioactivity in the 
supernatant was measured by liquid scintillation counting. 
3. Results 
Transcriptional activation and ligand-binding properties of 
AR were first studied in yeast cells. Full-length AR or various 
parts of LBD were fused to LexA, and the resulting expres-
sion vectors were used to transform L40 yeast cells, in which 
transcription of the P-galactosidase gene is under the control 
of LexA-binding sites. A fusion construct encompassing full-
length rAR activated the reporter gene by 140-fold in the 
presence of 50 nM testosterone (Table 1). The construct 
with LBD alone [pLexA-LBD(657-919)] was almost as active 
as full-length rAR, indicating that LBD contains indeed a 
transcription activation function termed AF-2. Transcription-
al activation occurred only in the presence of testosterone. 
Activation of the reporter gene by androgen was diminished 
to one-fifth, when residues containing the hinge region (624-
656) were present in the construct [pLexA-HLBD(624-919)]. 
No significant differences in androgen-binding capacity be-
tween the three receptor forms were observed: 700-800 recep-
tors per cell were determined for each construct. Interestingly, 
a 100-fold molar excess of two non-steroidal antiandrogens 
(casodex or hydroxyflutamide), which abolish the agonist-
dependent transcriptional activity of wild-type AR in mam-
malian cells [13,14], did not inhibit androgen-induced tran-
scriptional activity of either AR LBD or full-length rAR fused 
to LexA (Table 1). 
Transcription-activating and ligand-binding properties of 
several LBD mutants were next examined. pLexA-LBD(657-
919) was truncated by 10 amino acids at each end, yield-
ing pLexA-LBD(668-919) and pLexA-LBD(657-909). De-
letion of the first 10 amino acid residues from either the 
NH2-terminus or the COOH-terminus of LBD resulted in a 
complete loss of ligand binding that was accompanied by the 
loss of AF-2 (Table 1). Additional truncation at either end of 
LBD restored neither one of the two activities (data not 
shown). 
To study the function of AF-2 of AR in mammalian cells 
and to compare its transactivation properties with those ob-
served in yeast, LBD of hAR was cloned in-frame to the 
COOH-terminus of S. cerevisiae GAL4 DBD. The chimeric 
protein was expressed in CV-1 and CHO cells and tested for 
its ability to activate a reporter gene driven by GAL4-binding 
sites as cw-acting elements. The fold activation in the presence 
of testosterone in the culture medium was not clearly meas-
urable in CV-1 cells, as the LBD construct appeared to act as 
a repressor of transcription in the absence of androgen, 
whereas in CHO cells, transfected pGAL4-LBD brought 
about a modest 5-fold activation (over GAL4 DBD alone) 
of the reporter gene in the presence of steroid (Table 2). A 
100-fold molar excess of casodex or hydroxyflutamide inhib-
ited AF-2 function activated by androgen by 50% (Table 3). 
In SFY526 yeast cells, which carry a GAL4-responsive p-ga-
lactosidase reporter gene, pGAL4-LBD(657-919) exhibited 
transcriptional activity comparable to that of pLexA-
LBD(657-919), indicating that expression of AF-2 of AR 
did not depend on the partner to which LBD was fused. 
We next compared the transcriptional activity of the major 
AF-1 of hAR [15] to that of AF-2 as GAL4 DBD fusion 
proteins in yeast cells. GAL4-NT(141^107) was about 80-
fold more efficient in activating GAL4-responsive P-galacto-
sidase reporter gene than GAL4-LBD(657-919) in the pres-
ence of testosterone (Table 2). Activation by pGAL4-NT(141-
340) was significantly lower than that by pGAL4-NT(141-
407) and close to that achieved by ligand-bound pGAL4-
LBD(657-919). The N-terminal AF-1 is thus the major tran-
scription activation domain in both mammalian and yeast 
cells. Moreover, tethering of full-length AR through its ami-
no-terminus to LexA severely restrains the activity of AF-1 
(cf. Tables 1 and 2). 
Table 1 
Functional analysis of LexA-AR fusion proteins in Saccharomyces cerevisiae 
Chimeric protein construct 
LexA-rAR 
LexA-LBD(624-919) 
LexA-LBD(657-919) 
LexA-LBD(668-919) 
LexA-LBD(657-909) 
LexA 
Androgen 
+ 
+ 
+ 
-
-
— 
binding p-Galactosidase activity 
-Test 
<1 
<1 
< j 
<\ 
<1 
+Test 
140 ±1 
100 ±1 
21 ±0.5 
<1 
<1 
1 
+Cdx 
s i 
<1 
ND 
ND 
ND 
1 
+Flu 
£ l 
<1 
ND 
ND 
ND 
1 
+Test 
+Cdx 
175 ±34 
152 ±6 
ND 
ND 
ND 
1 
+Test 
+Flu 
115±15 
89 ±1 
ND 
ND 
ND 
1 
The numbers depict the amino acids of hAR or rAR fused in-frame to the COOH-terminus of LexA. Fusion proteins were expressed in yeast cells 
and ligand binding and transactivation properties were analyzed in the presence and absence of 50 nM testosterone (Test), 5 u,M casodex (Cdx) or 
5 uM hydroxyflutamide (Flu). ND = not determined. P-Galactosidase activities are expressed relative to LexA alone. Mean ± S.E.M. values of three 
independent experiments are shown. 
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Fig. 1. Schematic representation of LexA-AR and GAL4-AR fusion proteins used for transactivation studies in yeast and mammalian cells. 
(A) LexA fusion constructs. (B) GAL4 DBD fusion constructs. The numbers depict the amino acids of hAR or rAR (3-902) fused in-frame to 
the COOH-terminus of LexA or GAL4 DBD. NTD = amino-terminal domain; H = hinge region. 
4. Discussion 
We have investigated transactivation and ligand-binding 
properties of AR in yeast and mammalian cells. Our findings 
demonstrate, for the first time, that LBD of AR harbors a 
ligand-inducible activation function. Deletion of only 10 ami-
no acids from either end of LBD abolished both transcription 
activation and androgen binding, indicating that these two 
functions are connected. It is of note, however, that AF-2 in 
LBD as a separate domain is considerably weaker than the 
amino-terminal AF-1 both in yeast and mammalian cells, em-
phasizing the role of AF-1 as the major transactivation do-
main. A plausible explanation for the finding that extension of 
the LBD construct to include the hinge region (LexA-HLBD) 
lowers in yeast cells steroid-dependent AF-2 activity, but not 
steroid binding, is that the hinge region provides an interac-
tion interface for inhibitory proteins. 
Androgen-induced transcriptional activity of full-length AR 
fused to heterologous DBD was only marginally higher in 
yeast cells than that of LBD alone. Given the high inherent 
activity of AF-1 fusion protein, it is not likely that the attach-
ment of full-length AR through its amino-terminus to a het-
erologous DBD would cause incorrect folding of the AF-1 
region. A plausible explanation for the low activity of full-
length AR in this context is that its anchorage to another 
protein interferes with ligand-dependent interaction between 
the amino-terminal region and LBD [16] and/or retains the 
receptor in a conformation that cannot make proper contacts 
with auxiliary proteins. 
It was somewhat unexpected that two non-steroidal antian-
drogens, casodex and hydroxyflutamide, were not able to in-
hibit agonist-induced transactivation by LexA-LBD or LexA-
rAR in yeast cells or did so poorly in mammalian cells. These 
results may reflect the fact that antiandrogens bind very 
weakly to LBD and that this property, rather than expression 
of the full complement of biological actions of antiandrogens, 
was examined under the present experimental conditions. It is 
worth pointing out, however, that Kralli et al. have recently 
shown that an ATP-binding cassette transporter is capable of 
selectively decreasing intracellular levels and thereby biologi-
cal potency of some synthetic steroids in yeast [17]. In view of 
this, antiandrogen resistance in yeast cells may be, at least in 
part, due to selective efflux of these compounds by transporter 
protein(s). 
In conclusion, transactivation properties of AR in yeast 
cells are in many respects similar to those in mammalian cells, 
suggesting that principal coactivators or auxiliary proteins 
mediating the contacts between AF-1 or AR and general tran-
scription apparatus are conserved in these cells. However, the 
activity of AF-2 in the LBD can be demonstrated much better 
in yeast than in mammalian cell lines (CV-1 and CHO cells) 
examined in this work, possibly due to the presence of core-
Table 2 
Functional analysis of GAL4-AR fusion proteins in yeast cells and comparison of GAL4-LBD function in yeast and mammalian cells 
Reporter gene activity (arbitrary units) 
Chimeric protein construct 
GAL4-LBD(657-919) 
GAL4-NTD(141-407) 
GAL4-NTD(141-340) 
GAL4 
Androgen 
+ 
binding Yeast 
-Test 
< 1 
5510 ±707 
131 ± 13 
1 
+Test 
70±4 
ND 
ND 
1 
CV-1 
-Test 
0.1 
£ l 
ND 
1 
+Test 
1.3 
< 1 
ND 
1 
CHO 
-Test 
0.3 
ND 
ND 
1 
+Test 
4.6 
ND 
ND 
1 
The numbers depict the amino acids of hAR fused in-frame to the COOH-terminus of GAL4 DBD. Fusion proteins were expressed in yeast cells or 
in CV-1 and CHO cells, and assays for ligand binding in yeast cells and transactivation ability ± 50 nM testosterone (Test) in yeast and mammalian 
cells performed as described in Section 2. The reporter gene activities are expressed relative to GAL4 DBD (GAL4) alone. Mean ± S.E.M. values of 
three experiments in yeast cells and the mean of two experiments in mammalian cells are depicted. 
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Table 3 
Influence of antiandrogens on transcriptional activation mediated by 
pGAL4-LBD(657-919) in CHO cells 
References 
Androgen or antiandrogen (nM) Relative CAT activity 
Testosterone (50) 100 ± 22 
Casodex (5000) 13 ± 3 
Hydroxyflutamide (5000) 15 ± 7 
Testosterone (50)+casodex (5000) 55 ± 12 
Testosterone (50)+hydroxyflutamide (5000) 55 ± 11 
GAL4-LBD(657-919) fusion protein was expressed in CHO cells and 
its transactivation ability measured in the presence of testostero-
ne ± antiandrogen as described in Section 2. For the relative CAT 
activity, the value for GAL4-LBD(657-919) in the presence of 
50 nM testosterone was set as 100%. Mean ± S.E.M. values of three 
independent experiments are shown. 
pressor proteins in the latter. It remains to be elucidated 
whether these putative inhibitory proteins play any role in 
cell type- and/or development stage-specific expression of an-
drogen action. 
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